brexpiprazole vs paliperidone
Side-by-side comparison of brexpiprazole and paliperidone Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Rexulti
Invega
Rexulti is a medication used to treat certain mental health conditions. It can help with depression, schizophrenia, and agitation related to Alzheimer's disease.
Paliperidone extended-release tablets, also known as Invega, are a type of antipsychotic medicine. It helps manage symptoms of certain mental disorders.
Rexulti can be used with antidepressants to treat major depressive disorder in adults. It can also treat schizophrenia in adults and children 13 years and older. Additionally, Rexulti can help manage agitation in people with dementia due to Alzheimer's disease. Rexulti should not be used as needed for agitation related to dementia.
This medicine is used to treat schizophrenia in adults and teens (12-17 years old). It can also treat schizoaffective disorder in adults, either alone or with other medicines like mood stabilizers or antidepressants. Schizophrenia can cause hallucinations, delusions, and confused thinking. Schizoaffective disorder includes symptoms of both schizophrenia and mood disorders.
Rexulti affects the balance of certain natural chemicals in the brain. These chemicals, called neurotransmitters, include dopamine and serotonin. By affecting these chemicals, Rexulti can help improve mood, thinking, and behavior.
Paliperidone affects certain chemicals in the brain. These chemicals, like dopamine, can become unbalanced in people with schizophrenia and schizoaffective disorder. By acting on these chemicals, paliperidone helps to reduce symptoms.
- • Weight gain
- • Feeling sleepy
- • Restlessness or feeling like you need to move
- • Extrapyramidal symptoms (movement problems)
- • Fast heart rate
- • Feeling restless and unable to sit still
- • Sleepiness
- • Indigestion
- Weight gain 1,673
- Using the medicine for a condition it is not approved for 1,277
- Using the medicine for a condition it is not approved for 1,092
- The medicine is not working 929
- Restlessness or feeling like you need to move 854
- Physical harm or wound 4,330
- Enlargement of male breast tissue 3,664
- Medication not working 1,729
- Unusual increase in weight 1,660
- Using medication for a non-approved purpose 1,501
Elderly patients with dementia-related psychosis who are treated with antipsychotic drugs have an increased risk of death. Rexulti is not approved to treat dementia-related psychosis unless it is related to agitation from Alzheimer's disease. Antidepressants may increase the risk of suicidal thoughts and behaviors in young adults and children. Tell your doctor right away if you have thoughts of harming yourself.
This medicine has a boxed warning. It may increase the risk of death in elderly patients with dementia-related psychosis. Paliperidone is not approved to treat this condition.
Tell your doctor if you are pregnant or plan to become pregnant. Babies born to mothers who take Rexulti in the last 3 months of pregnancy may have withdrawal symptoms or other problems after birth. There is a pregnancy registry to monitor outcomes in women exposed to Rexulti during pregnancy. You can contact the registry at 1-866-961-2388.
If you are pregnant or plan to become pregnant, talk to your doctor. Babies born to mothers who use this medicine in the last 3 months of pregnancy may have withdrawal symptoms or movement problems after birth. There is a pregnancy registry to monitor outcomes in women exposed to atypical antipsychotics during pregnancy. You can contact the registry at 1-866-961-2388.
Also Compare — Nearby Drugs
Compare brexpiprazole with
Compare paliperidone with
How to Read This brexpiprazole vs paliperidone Comparison
brexpiprazole is classified in the Atypical Antipsychotic drug class, while paliperidone sits within the Atypical Antipsychotic class. Because both drugs share the same classification, they are often considered interchangeable in theory — but clinical outcomes rarely track that cleanly. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, brexpiprazole has 5,825 submissions while paliperidone has 12,884. Those figures reflect cumulative reporting volume — not per-patient risk — so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between brexpiprazole and paliperidone — always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.